News

According to the announcement, the interim results suggest that the vaccine candidate demonstrates efficacy within about 10 days of administration to a person without the infection. The VSV-ZEBOV

Thanks to its innovative formulas, the GelX range alleviates pain in oncological patients, offering different solutions for chemotherapy & radiation induced oral mucositis, xerostomia, dry mouth and radiation

This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The

The authors report that vaccine efficacy was 100 percent (95% confidence interval: 74.7 – 100%; p=0.0036) following vaccination with a single dose of the rVSV-ZEBOV vaccine. It appeared

The resubmission, which provides information to specifically address the FDA-issued complete response letter received in September 2013, includes the results from an additional pharmacokinetic trial that was conducted

In January, Cipher acquired the Canadian commercialization rights to ozenoxacin from Ferrer, a Spanish pharmaceutical company. A total of 412 adult and paediatric patients aged two months and

Having secured the IND designation, the company now intends to start a multi-center, pivotal Phase II trial soon to evaluate JCAR015 in patients with r/r ALL. Registration of

The new drug product is a formulation of dactinomycin indicated to treat Ewing’s sarcoma, a rare type of childhood bone cancer. Orphan drug designation was awarded to the

In the European Union (EU), Humira is now the first and only medication approved for HS, a painful, chronic inflammatory skin disease, also referred to as ‘acne inversa’.